Dr. Eduardo Beltrán is a seasoned professional with over a decade of academic experience specializing in human genomics. His expertise encompasses immunology, next-generation sequencing, and bioinformatics, resulting in significant contributions to prestigious journals.
Eduardo, in his role at BC Platforms, is actively engaged in expanding the global data partner network. He ensures secure access to high-quality Real-World Data (RWD) studies, excelling in integrating multidisciplinary knowledge. Eduardo is committed to developing and implementing efficient, secure methods for querying health data and deploying cutting-edge analytics solutions. His dedication lies in leveraging large-scale datasets to comprehensively understand disease mechanisms, with the ultimate goal of contributing to groundbreaking improvements in patients' lives.

Florent is a Ph.D. student at the Leibniz Supercomputing Centre and Technical University Munich. He works on privacy-preserving AI with an emphasis on confidential computing. His goal is to make machines learn and help save lives. He remains a biologist at heart, previously working on new technology applied to healthcare in the fields of nanotechnology, artificial organ design, and high throughput data processing. He is also an avid coder and tech hacker.

Dr. Stefan Ebener is managing an international team of experts for Google Cloud. His passion includes data-driven technologies and the development of technology competencies in companies and society. 

He is also a freelance lecturer in business informatics, a member of the Scientific Society for Market-Oriented Management, belongs to the Institute for IT Management & Digitization at the University of Economics & Management, is a startup mentor, author and keynote speaker.

Prof. Torsten Haferlach spent the first part of his career as a medical doctor and hematologist at the university clinics in Kiel and Göttingen, then at the university clinic in Munich (LMU) where he acted as both the senior physician at the Department of Internal Medicine and the Head of the laboratory for leukemia diagnostics.

In 2005, he set up the Munich Leukemia Laboratory (www.mll.com) together with three colleagues from complementary disciplines. Today the lab processes over 125,000 blood or bone marrow samples per year, his practice treats more than 5,000 patients, and more than 750 articles have been published in top ranking, peer‐reviewed medical journals since the lab’s inception.  Dr Haferlach is author or co-author of more than 690 peer-reviewed articles and also co-author of the new WHO Classification 2022.

The Munich Leukemia Laboratory (MLL) is a central reference laboratory providing diagnostic services for Germany and also for international studies in hematology.  The MLL offers services 7 days a week, including cytomorphology, cytogenetics, FISH, immunophenotyping and molecular genetics, including also WGS and WTS.

Mark is a highly experienced analytics professional based in Oxford, UK, with a remarkable 25-year career in the analytics industry. Over the past decade, Mark has primarily concentrated on designing and implementing Real-World Data (RWD) platforms. His expertise extends to solution architecture, RWD/RWE solution advisory, ETL tools/SQL, and TILING-based data warehousing. One of his standout strengths lies in cloud technologies, where he excels in optimizing cloud solutions and integrating them to enhance both performance and security. Furthermore, Mark has cultivated a successful track record of collaborating closely with reputable organizations such as ASCO CancerLinQ, research institutions and biobanks, hospital networks, and pharmaceutical clients worldwide, expertly connecting their needs with innovative solutions to address industry-specific challenges and regulatory demands. 

Ruth Horn is Deputy Director of the Institute of Ethics and History of Health in Society (IEHHS), University of Augsburg and Associate Professor at the Ethox Centre, University of Oxford. Her research focuses on ethical questions raised by medical practices and new technologies in different socio-cultural and political contexts (namely France, Germany and England). Her research interests range from ethical issues of data-driven health technologies - with a specific focus on genomics and prenatal testing - to ethical questions at the end of life. She is the president of the European Association of Centres of Medical Ethics (EACME), lead of the UK-FR+ Genomics and Ethics Network (GENE) and member of a variety of international committees (German Human Genome-Phenome Archive; BSGM Fetal Genome Group, UK;  Ethics Committee of the CNRS, FR; Oxford Tropical Research Ethics Committee, UK; Clinical Ethics Committee Augsburg, DE;…). She has been involved in a number of policy documents, such as lately the UK Joint Committee on Genomics in Medicine’s Ethical Guidelines on Prenatal Diagnosis.

Jens Krüger is head of the High Performance and Cloud Computing Group at the IT Center of the Eberhard Karls Universität Tübingen. As such, he and his team operate the de.NBI Cloud Tübingen as well as the bwForCluster Binac, the Core Facility Cluster of the university along with other infrastructures. He is involved as co-speaker, coordinator, operator or similar in DataPLANT, GHGA, 4Memory, EOSC-Life, HealthyCloud, BioDATEN, IRTG2804 Women’s Mental Health, TRR356 PlantMicrobe and bwHPC.

His research interests cover a broad range from molecular simulations of membrane proteins, over sensible annotation of research data, efficient workflow handling, user friendly science gateways to GDPR-compliant processing environments.

Dr. Lotfollahi recently completed a PhD in Computational Biology at the Technical University of Munich (TUM) and Helmholtz Munich. He is also a European Laboratory for Learning and Intelligent Systems member. He is currently the Director of Machine Learning Research at Relation Therapeutics in London and is a scientist at Helmholtz Munich. Additionally, he is an incoming faculty member at the Wellcome Sanger Institute. His research focuses on developing AI/ML algorithms for biomedical data, specifically emphasising single-cell technologies for diagnostics, therapeutics, and drug discovery applications. He has received multiple awards for his research, as evidenced by his notable achievements, and has been featured in the press and journals, as outlined in his research. Furthermore, Dr. Lotfollahi has been granted multiple fellowships, grants, and scholarships, including those from Joachim Herz, EMBL, and Meta.

Prof. Makowski is the director of the Department of Diagnostic and Interventional Radiology at the Klinikum rechts der Isar of the TU Munich since 2020. His scientific focus is on quantitative imaging and the application of AI methods in radiology. His experimental scientific focus is on quantitative molecular imaging with a focus on ECM and immunoimaging. His clinical focus is on the evaluation and establishment of new quantitative biomarkers in radiology using imaging data. After studying human medicine, Prof. Makowski completed his dissertation at the LMU Munich in 2007. He successfully completed his PhD studies at King's College London, School of Medicine, London in 2010. In 2013, his habilitation (Charité) was awarded the Wilhelm Conrad Röntgen Prize. In 2016, he received an appointment to a W2 Heisenberg Professorship (Charité). For his clinical training, he worked in the Department of Radiology at Charité, which he left as Deputy Clinic Director with an appointment to TU Munich.

Dr. Henrik Matthies ist CEO und Co-Founder von Honic, der souveränen, DSGVO-konformen Forschungsdatenplattform ‚made in Germany‘. Bis Ende 2021 war er Managing Director des health innovation hubs des Bundesministeriums für Gesundheit, zuvor hat er erfolgreich mehrere Startups mitgegründet und aufgebaut, mit Mimi Hearing Technologies einen der Digital Health Pioniere in Deutschland und Europa.

Andreas Pichlmair studied Veterinary Medicine in Vienna, where he got in excited by viruses and their ability to cause disease. Following graduation he joined Otto Haller’s Laboratory  (Uniklinik Freiburg/Breisgau) for his doctoral degree (Virology) and Caetano Reis e Sousa (CRICK, London, UK) for his PhD (Molecular Immunology and Immunopathology). Thereafter he joined Giulio Superti-Furga at the Center for Molecular Medicine (Vienna, Austria) where he got exposed to large-data analysis. 2011 Andreas Pichlmair got recruited as Group leader to the Max-Planck Institute for Biochemistry (Munich, Germany) and moved as associate prof. to TUM in 2017. He is combining his expertise in virology, immunology and omics analysis to understand viral perturbation of host organisms and associated diseases. His current research focus lies in the leverage of omics data to identify biomarkers of disease progression and to identify novel treatment options.

As Head of Digital Health at Deutsche Telekom Healthcare Solutions, Monika Rimmele and her team are responsible for the Digital Health Portfolio at Europe´s biggest telco. She is passionate about redefining healthcare and focuses on future health topics such as digital transformation, platform technologies and digital therapeutics.

Monika is a political scientist with a Master of Public Policy (MPP) from the Hertie School in Berlin. Over the course of her career, Monika has worked in the digital health scene, the German government, associations, and industry actors, including the German Federal Ministry of Health, the German Association of Health IT Vendors (bvitg), Siemens Healthineeers and, most recently, as Managing Director at DiGA Factory.

Seit 2021 Vorsitzender des Arbeitskreises Medizinischer Ethikkommissionen in Deutschland.

Seit 1992 Mitglied und seit 2012 Vorsitzender der Ethikkommission der  Technischen Universität München.

Forschungsschwerpunkte:
Herzrhythmusstörungen, autonome Funktion, Risikoprädiktion, Biosignalverarbeitung (Publikationen siehe https://scholar.google.de/citations?user=-pJnz5sAAAAJ&hl=de).

With a double degree in Medicine and Pharmacy, Harald Schmidt works in network and systems medicine to re-define what we call "disease" from a descriptive symptom- and organ-based to a mechanism-based approach by using big data, multi-target validation, new mechanism-based diagnostics, and rapid repurposing of registered drugs for new clinical applications by network pharmacology. He applies this to areas of unmet medical need, such as the development and commercialization of a first-in-class neuroprotective therapy in stroke, a therapy against a common and untreatable form of heart failure, and a therapy for resistant hypertension. He coordinates the H2020 project REPO-TRIAL on in-silico network pharmacology and the organ-agnostic European drug repurposing platform project REPO4EU. He was awarded an ERC AdG, and an ERC PoC grant, and chaired two COST actions. He co-founded the journals ‚Drug Repurposing‘ and ‚Network Medicine‘ and is on the Harvard-led Network Medicine Alliance board. His multi-national research experience in Academia (Germany, USA, Australia, Netherlands), Industry (Abbott Labs), and Biotech (Vasopharm) have led to high-impact publications (Hirsch index 102) with high socio-economic relevance such as drug and diagnostics patents, spin-offs and patient benefit. He has trained several successful scientists and clinical leaders and is a research- and evidence-based teacher, speaker, podcaster, and author (The End of Medicine As We Know It, Geheilt statt behandelt).

Heribert Schunkert, MD is Professor of Cardiology of the Technische Universität München and Director of the Cardiology Department, German Heart Centre Munich since 2012. He completed a research fellowship at Brigham and Women’s Hospital, Boston, USA and clinical fellowships at Beth Israel Hospital, Universitätsklinikum Regensburg, and the Massachusetts General Hospital, Boston, USA, before he became assistant and associate professor in Regensburg. From 2002-2012 Prof. Schunkert was Director of Internal Medicine and Cardiology at the University of Luebeck. He conducts research in the molecular genetics of multifactorial cardiovascular disease, coordinates several EU- and BMBF-sponsored projects as well as the European-American Leducq network CADgenomics to identify the genetic roots of myocardial infarction. He is the author of more than 700 publications in international journals.

Sophia Steigerwald received her Bachelor's and Master of Science degrees from the Technical University Munich in Molecular Biotechnology and Biochemistry respectively. For her master thesis she worked in the Mass Spectrometry for Quantitative Proteomics Group at the Novo Nordisk Foundation Center for Protein Research under the supervision of Prof. Dr. Jesper Olsen on dynamic protein sub-cellular localization by mass spectrometry (MS) as well as MS technology. She is currently doing her PhD as an IMPRS graduate student at the Max Planck Institute for Biochemistry in Martinsried, Germany, were she works under the supervision of Prof. Dr. Matthias Mann. Her PhD research focuses on MS technology, method development and clinical proteomics in the context of cardiovascular diseases. As part of the DigiMed Bayern consortium, she works in close collaboration with the clinical consortium members to study disease-based differences in protein expression and to identify potential protein biomarkers.

In 2014, together with Arnoud van der Maas, CSIO of Radboudumc, Stefan laid the foundation of the concept Digital Research Environment (DRE). A solution for the group of researchers best served by trusted, tool and data agnostic environments in which easy collaboration, including with externals, is possible. In 2015 Stefan was responsible for the European Tender and during this time, the job turned into a passion: helping the research ecosystem to deal with that particular group of researchers. In 2019 Stefan became CTO of anDREa consortium, a collaboration of three UMCs, that resulted in a spin out in 2021. Servicing now every month over 1,600 active researchers, working from 26+ countries in studies of 10 research institutes. Stefan works actively on his dream to extend anDREa’s services to other European Research Institutions. Trust, unburden, and empowerment are key, and with respect to trust, Stefan is personally committed to contributing to bodies that objectively will certify solutions and companies that want to operate in the research ecosystem and to bodies committed to standardisation agreements for Research Institutions. Data, large or small, will only be accessible if there is trust. Trust is objectified and made measurable and is useful for minimal CISOs, DPOs, Legal, and not in the least the interest groups.

Moritz von Scheidt is a clinician scientist and cardiologist at the German Heart Center Munich of the Technical University of Munich. As a research fellow at the University of California Los Angeles (UCLA) he studied atherosclerosis in genetically engineered mouse models in direct comparison to human coronary artery disease supervised by Prof. Jake Lusis. He received an excellence grant from the German Centre of Cardiovascular Research (DZHK), third party funding by the German Society of Cardiology (DGK) and the German Heart Foundation (Deutsche Herzstiftung e.V.). In 2021 he received a young investigator award by the Leducq foundation and was awarded with the Uta and Jürgen Breunig Research Price for the mechanistic identification of the transcription factor MAFF as an inflammatory dependent regulator of the LDL-receptor. In 2022 he started his own Junior Research Group studying somatic mutations in cardiovascular disease funded with 1.0 million Euro by the CORONA Foundation. He is initiator and head of the MunIch CardiovaScular StudIes biObaNk (MISSION) – one of the largest human cardiovascular tissue biobanks with access to human coronary samples. His research aim includes the translation from genetics into functional biology, including the identification of biomarkers and potential treatment strategies. 

Jens joined Bio^M in early 2018 to help setting up the Bavarian P4 medicine flagship project DigiMed Bayern. Since it’s start he is heading DigiMed Bayern operational part as Managing Director. The project aims to implement digitally driven predictive, preventive, personalized and participatory medicine of the future in the examplary field of atherosclerotic diseases. It is funded by the Bavarian State Ministry of Health and Care with a total of above € 24 Mio with runtime until 2024.

In addition, Jens supports Bio^M and the Bavarian Biotech Cluster with his expertise in international Business Development and Digital Health.

2006 to 2018 he was responsible for setting up and scaling DNA-related services within different companies of the Eurofins group. This comprised DNA-Forensics, ancestry and paternity testing as well as animal and plant breeding, food analysis and cell genotyping. 2001 to 2006 he worked in Sales and Product Management for the Munich area based SME Biomax Informatics AG.

Jens has a PhD in Protein Engineering from the Gene Center of the Ludwig Maximilian University of Munich and a Diploma in Biology (Population Genetics) from Christian-Albrechts-Universität zu Kiel.

Ramin Yahyapour is Professor of Applied Computer Science at the Georg-August University of Göttingen since 2011. His research interests lie in eScience and infrastructures for collaborative, data- and computational-intensive research, as well as artificial intelligence. He publishes regularly at relevant journals and conferences.

Prof. Yahyapour is Chief Information Officer of the University Medical Center and the University of Göttingen. In this role, he is jointly responsible for the site's digitization strategy. He is speaker of the board of the Campus Institute Data Science at the University of Göttingen.

Ramin Yahyapour is managing director of the Gesellschaft für wissenschaftliche Datenverarbeitung mbH Göttingen (GWDG), the joint IT competence and computing center of the Max Planck Society and the University of Göttingen. The GWDG provides various computing and data services for the Göttingen campus and beyond, i.e. in various national infrastructures. The GWDG is one of nine National High Performance Computing Centers (NHR), one of the National AI Service Centers and partner of several consortia of the National Research Data Infrastructure (NFDI). GWDG is also a partner and operator site of the German Aerospace Center for High-Performance Computing.

Naweiluo Zhou is a research scientist at Leibniz Supercomputing Centre. Before joining LRZ, Naweiluo has worked in different countries with main research interest in exploiting HPC and Cloud technologies to address the challenges in different domain science. Naweiluo has a mixed academic background, holding a PhD in computer science from Grenoble Alpes University and French Institute for Research in Computer Science and Automation, master degrees in electric engineering and computer science from the University of Manchester and the University of Nottingham, and a bachelor degree in Biomedical Engineering from Sichuan University, China.